Patents by Inventor Iwan Beuvink

Iwan Beuvink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
    Patent number: 11851484
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: December 26, 2023
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
    Publication number: 20210246200
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Application
    Filed: December 17, 2020
    Publication date: August 12, 2021
    Applicants: Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
    Patent number: 10889643
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: January 12, 2021
    Assignee: Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
    Publication number: 20190016797
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Application
    Filed: January 11, 2017
    Publication date: January 17, 2019
    Applicants: Novartis AG, Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • COMPOSITIONS AND METHODS TO TREAT MUSCULAR & CARDIOVASCULAR DISORDERS
    Publication number: 20120114744
    Abstract: The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.
    Type: Application
    Filed: January 18, 2012
    Publication date: May 10, 2012
    Applicant: NOVARTIS AG
    Inventors: Iwan BEUVINK, Jonathan HALL, Jan WEILER, Christian SCHNELL, Matthias MUELLER, Martina SCHINKE-BRAUN, Fabrizio SERLUCA
  • Compositions and Methods to Treat Muscular & Cardiovascular Disorders
    Publication number: 20120041052
    Abstract: The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.
    Type: Application
    Filed: August 9, 2011
    Publication date: February 16, 2012
    Applicant: NOVARTIS AG
    Inventors: Iwan BEUVINK, Jonathan HALL, Jan WEILER, Christian Rene SCHNELL, Matthias MUELLER, Martina SCHINKE-BRAUN, Fabrizio SERLUCA
  • Methods for Detecting Oligonucleotides
    Publication number: 20110097716
    Abstract: The invention provides methods and compositions for detecting and/or quantifying nucleic acid oligonucleotides. These methods and compositions are useful for detecting and quantifying diagnostic and/or therapeutic synthetic target oligonucleotides, such as aptamers, RNAi, siRNA, antisense oligonucleotides or ribozymes in a biological sample.
    Type: Application
    Filed: August 21, 2009
    Publication date: April 28, 2011
    Applicant: Novartis AG
    Inventors: Francois Jean-Charles Natt, Iwan Beuvink, Andrew Geall
  • COMPOSITIONS AND METHODS TO TREAT MUSCULAR & CARDIOVASCULAR DISORDERS
    Publication number: 20100280094
    Abstract: The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.
    Type: Application
    Filed: December 13, 2007
    Publication date: November 4, 2010
    Inventors: Iwan Beuvink, Jonathan Hall, Jan Weiler, Christian Schnell, Mathias Mueller, Martina Schinke-Braun, Fabrizio Serluca
  • p53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent
    Patent number: 7749698
    Abstract: Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the integrity of DNA.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: July 6, 2010
    Assignee: Novartis AG
    Inventors: Iwan Beuvink, Anne Boulay, Heidi Lane, Terence O'Reilly, George Thomas
  • P53 Wild-Type as Biomarker for the Treatment with Mtor Inhibitors in Combination With a Cytotoxic Agent
    Publication number: 20080194613
    Abstract: Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the integrity of DNA.
    Type: Application
    Filed: February 22, 2005
    Publication date: August 14, 2008
    Inventors: Iwan Beuvink, Anne Boulay, Heidi Lane, Terence O'Reilly, George Thomas